TQH2722 injection

DRUG4 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Conditions

Atopic DermatitisSeasonal Allergic Rhinitis

Phase 1

A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Atopic Dermatitis

Start: 2022-06-30End: 2023-08-31Target: 48Updated: 2022-06-08

Phase 2

Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis

CompletedNCT06760182

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Seasonal Allergic Rhinitis

Start: 2025-03-10End: 2025-07-01Updated: 2025-08-12

Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis

RecruitingNCT07398859

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Seasonal Allergic Rhinitis

Start: 2026-03-19End: 2027-03-01Target: 300Updated: 2026-03-27

Phase 3

To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Active, not recruitingNCT06552520

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Atopic Dermatitis

Start: 2024-10-08End: 2026-06-01Updated: 2026-04-20

Related Papers

565 – Safety and pharmacokinetic profiles of a humanized monoclonal antibody TQH2722 targeting interleukin 4 receptor alpha (IL-4Rα) in health adult subjects

British Journal of Dermatology2024-02-011 citations